Skin-Sights from Fall Clinical

Welcome to this week's edition of Dermatology Times' LinkedIn newsletter!

This week, Dermatology Times traveled to Las Vegas, Nevada, to attend and cover the 44th Annual Fall Dermatology Conference. Our team spoke with session speakers and expert dermatologists who addressed numerous topics of interest. View our comprehensive conference coverage here. If you'd like to keep up with conference pearls and insights as they happen live, be sure to sign up for our e-newsletter.

If you have questions, suggestions, or would like to contribute to a future edition, please contact us via LinkedIn or via email at DTEditor@mmhgroup.com.

💡 Expert Insights - CONFERENCE EDITION

Explore clinical conference insights from: Raj Chovatiya, MD, PhD, MSCI , James Q. Del Rosso, DO , Mona Shahriari, MD, FAAD , Shawn Kwatra , MD, Joel M Gelfand MD MSCE , Aaron S. Farberg, MD , Eingun James Song, MD, FAAD , Emmy Graber , MB, MBA, Christopher Bunick , MD, PhD, and glynis ablon , MD.

"It seems like year after year there's an exponential increase in not only new mechanisms of action that I'm really excited to hear about, but also new, innovative and practical ways to maybe use some of our old favorites as well."

"We’re changing lives with the therapies that we have."

"I always say, 'What happens in Vegas transforms dermatology.'"

"Every dermatologist, every physician, every provider who takes care of dermatology patients should be asking their patients about itch."

"Phototherapy has a role to play for helping our patients get better outcomes."

"I lead and started the early career dermatology initiative. Why? Well, I'm early career. Of course, I see and understand the value of the younger dermatologist. We are the future, and we want to make sure that they get more unique and personalized education"

"There's really been a large unmet need for highly effective and well-tolerated non steroidal agents, not just for psoriasis, but particularly for atopic dermatitis. I'm pleased that we have now several options in the AD space."

"We have these new lasers, which are of the 1726 nanometer wavelength, which directly target sebum, thus selectively destroying the sebaceous gland while keeping the epidermis intact. This means that we can safely treat the skin without causing damage that we don't want."

"This new standard of care in atopic dermatitis - hitting EASI 90 and itch 0/1 - is moving the bar higher."

"Patients are always looking for something that doesn't hurt... something that's fast and can be done literally with no downtime whatsoever."

🚨 Breaking News Brief

The phase 3 trial met primary and secondary endpoints, with significant improvements in ISS7 and UAS7 scores compared to placebo.

A significant proportion of patients maintained stable therapeutic responses, achieving low EASI, DLQI, and pruritus NRS scores.

By week 32, 79.6% achieved EASI 75, 58.7% EASI 90, and 19.9% EASI 100 after switching to upadacitinib.

Rapid efficacy was observed, with significant improvements in SCORAD, POEM, and DFI scores within one week of treatment.

🧬 Research Roundup

This review of the latest dermatologic studies includes discussions on the development of the Hand Eczema Impact Scale, the role of tofacitinib on Th1 and Th2 cytokines, and more.

The study surveyed 298 parents, revealing that 58% reported no food-related exacerbation of eczema, with milk, nuts, and eggs as common triggers.

The application of a clinically validated moisturizer before mask-wearing was shown to significantly improve skin barrier function and reduce irritation.

📚 Continuing Education Opportunities

Discover ways to further your education and knowledge of specific disease states by exploring CME opportunities from Physicians' Education Resource®, LLC (PER®) below.

For more information, visit PER's website or click on the graphics below.

Thank you for reading!